CancerCare Manitoba
News Item

April 22, 2015

Leukemia Research Receives Significant Support

Research Manitoba Grant solidifies position of Manitoba researchers as national leaders

CancerCare Manitoba's (CCMB) research into the most common type of leukemia in adults received a $2.5 Million investment from Research Manitoba, solidifying CCMB's position as a national leader in Chronic Lymphocytic Leukemia (CLL) research. The grant enables a research cluster of Manitoba experts who will develop new therapies and patient management strategies.

"We are grateful for Research Manitoba's support of our integrated, multidisciplinary research cluster," said Dr. Sri Navaratnam, president and CEO of CancerCare Manitoba. "This timely support builds upon CancerCare Manitoba's efforts to expand the scope of cancer research in Manitoba, for the benefit of Manitobans."

Chronic Lymphocytic Leukemia is a blood and bone marrow disease. It is one of the most common types of leukemia in adults, usually occurring after middle age. It is more common in men than women.

"This unique cluster approach to CLL research will bring together researchers, government decision makers, patients, primary care providers and cancer specialists to improve the survival of CLL patients," said Dr. Spencer Gibson, Director of CCMB's joint cancer research centre with the University of Manitoba.

CancerCare Manitoba is a national leader in CLL research and clinical care. Led by Dr. James Johnston, Manitoba's CLL researchers and clinicians are internationally recognized, including an annual CLL conference in Winnipeg attended by researchers from around the world.

"This support for research for CLL will lead to better care for our patients," said Dr. Johnston. "Our joint efforts will further enhance our research efforts, translating into meaningful improvements for patients, such as more clinical trials, better treatment approaches, resulting in better clinical outcomes and better quality of life."

CancerCare Manitoba's Chronic Lymphocytic Leukemia clinic provides care and treatment to 800 patients. Approximately 100 new CLL patients are diagnosed each year.

Click here to view CancerCare Manitoba News Release

Click here to view Manitoba Government News Release (external site)

For additional information contact:
Jackie Shymanski
Director, Communications & Public Affairs
CancerCare Manitoba
Ph: 204 330 6575

Click here to view current news items

Click here to view archived news items